A. Blunt

Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.

J. Tabernero, A. Cleverly, T. Macarulla, 2013 .

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

J. Tabernero, J. Trojan, H. Oettle, 2018, British Journal of Cancer.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

J. Tabernero, J. Trojan, H. Oettle, 2018, British Journal of Cancer.

A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

J. Tabernero, J. Trojan, H. Oettle, 2016 .

Abstract CT068: A randomized phase II, double-blind study to evaluate the efficacy and safety of galunisertib+gemcitabine (GG) or gemcitabine+placebo (GP) in patients with unresectable pancreatic cancer (PC)

J. Tabernero, H. Oettle, D. Melisi, 2016 .